Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2000

View Archived Issues

AVI BioPharma to receive two grants to fund NeuGene antisense program

DuPont and Emisphere reach agreement on oral heparins

Aquila enters licensing agreement with Beth Israel for immune system-enhancing antibodies

Tamoxifen for DCIS granted FDA approval

Piboserod inhibits increased defecation under stress in preclinical study

Cel-Sci's Multikine improves cell-mediated immunity in HIV-infected patients

Amarillo Biosciences and Hayashibara to develop inhalable interferon gamma

JTV-519 improves contractile recovery after ischemia-reperfusion

FDA authorizes HemispheRx Biopharma trial for multidrug-resistant HIV

Positive results reported by Biovector from second phase I trial of nasal flu vaccine

Abbott licenses novel antimitotic agent from Eisai

Efficacy of FK-463 in disseminated azole-resistant candidiasis in mice

Aronex files NDA amendment for Atragen as treatment for APL

SkyePharma grants Paladin exclusive Canadian rights for DepoCyt

First step in the development of a probe for monitoring, diagnosing AD in living patients

Chimeric peptide exerts analgesic effects without tolerance development

Chronic AF-150(S) associated with cognitive and behavioral improvement in aged primate model

CPMP grants positive opinion for Actos as treatment of type 2 diabetes

Role for raloxifene in postmenopausal women with Alzheimer's disease

Effects of AWD-12-281 in preclinical models of asthma and COPD reported in Lisbon

Inhibition of peptido-leukotrienes by olopatadine may account for antiallergic effects

Herbal medicine modulates cytokine production and ameliorates ConA-induced hepatitis

SmithKline presents new tachykinin receptor antagonists, their synthesis and use

CCR3 receptor antagonists from Roche reportedly useful in asthma

Merck KGaA describes new series of compounds for thrombotic disorders

New inhibitors of Abeta production patented by Takeda

Schering-Plough patents new group of vitronectin receptor antagonists

Potent dopamine D2 receptor antagonists designed by Pierre Fabre for use in schizophrenia

Anticoagulant 2-pyridones under study at Sanofi-Synthelabo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...